BASF picks up omega-3 maker; Sigma dislikes Pfizer distributing direct to pharmacies;

> Zhejiang Hisun Pharmaceutical has a deal to commercially manufacture Celsion's heat-activated liposomal encapsulation of doxorubicin, used for the treatment of various cancers. Story

> BASF has bought Equateq, which has a manufacturing plant in Scotland with 47 employees where its makes highly concentrated omega-3 fatty acids for the pharmaceutical industry. Item

> The drug wholesaler Sigma Pharmaceuticals is raising concerns in Australia that a policy requiring drugs to be available within 24 hours is in jeopardy if companies follow Pfizer's lead in bypassing wholesalers and delivering drugs directly to pharmacies. Story

> Tibet Pharmaceuticals ($TBET), which manufactures traditional Tibetan medications, has an agreement with wholesaler Anhui Taihe Pharmaceutical Group, which has a network across 16 provinces and municipalities in China. Announcement

> India's top drug regulator is being investigated for letting pharmaceutical manufacturers, including some of the world's largest, go to market with drugs with little or no clinical testing. Story

> Jubilant HollisterStier has nailed down 5-year agreements to manufacture and distribute two products for Lantheus Medical Imaging. Item

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.